AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05983445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprospan
Description: 7mg i.m.
Study NCT05605756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 145 UNT [Botox]
Description: Botulinum A toxin injection: Will follow the FDA-approved guideline of the treatment of chronic migraine. The following modifications are planned: (a) Total units 145 instead of 155. (b) Number of injection sites 29 instead of 31. (c) the 6 injection sites in the trapezius muscle will be eliminated as they are irrelevant to our attempt to reduce seizure events. Instead, 4 injections will be made subcutaneously along the superior sagittal suture (see figures below), where no muscles exist and thus no muscle weakness is likely. This dose (145 Units) is well below the FDA-approved guideline on safety for adolescents and adults (no more than 10 Units/Kg or a total of 340 Units).~Botox injections will take place in the BIDMC Headache Clinic which is a part of the Arnold Pain center at 1 Brookline Place. Injections will be administered by Dr. Sait Ashina, the Director of the Headache Clinic.
Study NCT05580094 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: general anesthesia only.
Description: induction of general anesthesia by propofol and maintenance sevoflurane.
Study NCT05580094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia plus supraclavicular block.
Description: induction of general anesthesia by propofol and maintenance sevoflurane then the patients will receive the supraclavicular block with bupivacaine 0.5 ml per kg.
Study NCT04822363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Low dose aspirin in Arms A and D and High Dose Aspirin in Arm B
Study NCT04822363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Arms C and E
Study NCT06259981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLY-200
Description: 2.0 g GLY-200 (4 x 0.5 g capsules) orally twice daily
Study NCT06259981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 placebo capsules orally twice daily
Study NCT06542263 — intervention group
Intervention type: DEVICE
Intervention: CPAP
Description: For the non-CPAP group, the intervention includes catheter ablation and conventional treatment for AF combined with OSA; For the CPAP group, the intervention includes catheter ablation and CPAP treatment for AF combined with OSA
Study NCT05193461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed mood radiofrequency on dorsal root ganglion
Description: 3) Pulsed radio frequency (PRF): PRF of the dorsal root ganglion (DRG) will be performed to all participants in this study. The procedures will be performed in the operating room under fluoroscopic guidance following radiation safety standards. The dorsal root ganglion of lumbosacral roots will be targeted. The patients will be positioned prone .Lidocaine 1% will be infiltrated at the skin entry site. A 10 cm, 22-gauge radiofrequency needle with a 5 mm curved active tip will be used. A radiculogram will be done to confirm appropriate placement and DRG will be stimulated for confirmation of the appropriate nerve root involved. Proximity of the needle to the DRG will be determined by appropriate sensory stimulation with 50 Hz (0.4-0.6 V), and motor stimulation at 2 Hz will be used to determine a threshold 1.5-2.0 times greater than the sensory threshold to avoid placement near the anterior nerve root. A pulsed lesion will be generated by applying 45 V to the DRG for 6 minutes at 42°C.
Study NCT04308785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg intravenously on the first day of each 21-day cycle.
Study NCT04308785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered at a dose of 600 mg intravenously on the first day of each 21-day cycle.
Study NCT04308785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to tiragolumab will be administered at a dose of 600 mg intravenously on the first day of each cycle.
Study NCT04986982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg
Description: Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
Study NCT04986982 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
Study NCT05450692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Participants will receive ceralasertib oral tablets.
Study NCT05450692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive durvalumab as an intravenous infusion.
Study NCT05787821 — intervention group
Intervention type: DEVICE
Intervention: Total Knee Arthroplasty
Description: Total knee replacement.
Study NCT05290220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: 12 mg (BW≥60 kg) or 8 mg (BW \<60 kg)
Study NCT05632172 — intervention group
Intervention type: PROCEDURE
Intervention: implant insertion
Description: bone level dental implant insertion
Study NCT05969210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toe strengthening exercise
Description: 12 participants will be in experimental group giving them Toe strengthening exercise protocol along with running training for three weeks, measure all values before giving them protocol and after protocol.
Study NCT05969210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: 12 participants will be in control group they will do only there running training.
Study NCT05011032 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Homocysteine
Description: It is an amino acid which is synthesized by the demethylation of dietary methionine. It is a highly reactive, Sulfur-containing amino acid as a by-product of metabolism of essential amino acid specifically methionine. It was proved to be a strong risk factor causing many cardiovascular diseases, neurological disturbances and other health related issues
Study NCT05011032 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Homocysteine
Description: It is an amino acid which is synthesized by the demethylation of dietary methionine. It is a highly reactive, Sulfur-containing amino acid as a by-product of metabolism of essential amino acid specifically methionine. It was proved to be a strong risk factor causing many cardiovascular diseases, neurological disturbances and other health related issues
Study NCT04976972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVIO/CORI Surgical System
Description: Total knee replacement with robotic assistance
Study NCT04976972 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-robotic conventional instrumentation
Description: Total knee replacement with non-robotic conventional instrumentation
Study NCT04828525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: adjuvant dexamethasone treatment
Study NCT04828525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: placebo
Study NCT05895500 — intervention group
Intervention type: DRUG
Intervention: Injection for SC administration (120mg/syringe)
Description: Injection
Study NCT05895500 — intervention group
Intervention type: DRUG
Intervention: Tablet (50mg/tablet), oral
Description: Tablet
Study NCT04909255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: use beta-3 agonist for sjogren syndrome patient
Study NCT04909255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxybutynin, tolterodine, solifenacin
Description: use anti-muscarinic agent for patient with overactive bladder syndrome
Study NCT05577104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Description: For patients in the NPWT group, the wound bed preparation was facilitated by vacuum-assisted closure (VAC).
Study NCT05577104 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional moist dressings
Description: For patients in the control group, the wound bed preparation was facilitated by conventional dressing change method (with alginates ).
Study NCT05451888 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spa treatment
Description: A 40 minute period of lying in the spa treatment pool
Study NCT05451888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spa treatment
Description: A 40 minute period of lying in the spa treatment pool
Study NCT06185049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROCARE+ (Core intervention with add-on modules) and two booster sessions.
Description: The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors. It will include two booster sessions at 6 and 12 months into the intervention.
Study NCT06185049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROCARE+ (Core intervention with add-on modules) and one booster session
Description: The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors. It will include abooster sessions at 6 months into the intervention.
Study NCT06185049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROCARE+ (Core intervention with add-on modules) without booster sessions.
Description: The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors.
Study NCT04708145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Intravitreal 2mg aflibercept injection
Study NCT06052267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-56248
Description: Fluticasone Propionate/Salbutamol Sulfate. Oral inhalation powder.
Study NCT06052267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol sulfate
Description: Oral inhalation powder
Study NCT05450692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Participants will received docetaxel as an intravenous infusion.
Study NCT06319482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proactive CPAP Therapy
Description: CPAP machine uses Artificial Intelligence to make predictions and preventions of future apneic events to auto-adjust pressure.
Study NCT06319482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional APAP Therapy
Description: CPAP machine relies on the detection of respiratory events to determine how to react and auto-adjust pressure.
Study NCT05320146 — intervention group
Intervention type: OTHER
Intervention: MRI-PDFF
Description: Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a MRI-based diagnostic imaging biomarker of the liver.
Study NCT05816564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) for depression
Description: Both groups will be asked to engage in mindfulness activities but only one group will receive the train-positive ABM task. The control group will receive a sham task that is not programmed to train attention towards positive stimuli.
Study NCT05816564 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sham Attention Bias Modification (ABM)
Description: The sham intervention will be given to the control group (but they will still receive mindfulness exercises).
Study NCT04666883 — intervention group
Intervention type: OTHER
Intervention: Review of records and follow up
Description: Follow up to identify patients who developed splenic hilar nodal metastases
Study NCT05833880 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self-administered questionnaire
Description: Self-administered questionnaire regarding complementary and alternative medicine use
Study NCT05324215 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversalis fascia plane block and rectus sheath block
Description: Transversalis fascia plane block and rectus sheath block will be administered after the surgery.
Study NCT05324215 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intravenous fentanyl patient control device
Description: 24-hour fentanyl consumption will be recorded.
Study NCT05324215 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fentanyl patient control device
Description: 24-hour fentanyl consumption will be recorded.
Study NCT05063370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: Patients will receive Levosimendan infusion 12 hours before surgery in the ICU at a dose of 0.2 μg kg/min for the first hour and then reduced to 0.1 μg kg/ min to be continued in the operating room and then in the ICU (total infusion time of 24 hours).
Study NCT05063370 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard Care
Description: Patients will not receive Levosimendan and will receive standard care according to the institution protocol
Study NCT06493942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BioCoat® by Premier®
Description: BioCoat is a 56% filled resin formula that provides added strength and excellent long-term resistance to wear ؤomparable to flowable composites.
Study NCT06493942 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UltraSeal XT™ plus by Ultradent
Description: UltraSeal XT plus is a 58%-filled resin fluoride-releasing sealant. It is strong and has high wear resistant
Study NCT05320588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO-106
Description: BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)
Study NCT05320588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Programmed death receptor-1 (PD 1)-blocking antibody
Study NCT05316987 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Narrow band ultraviolet B
Description: 48 sessions of narrow band ultraviolet
Study NCT04700462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sm-EMA
Description: Self-monitoring ecological momentary assessment behavior change tool to promote adherence to a desired behavior (i.e. COVID-19 preventative behaviors).
Study NCT05426343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Description: Approximately 125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
Study NCT05426343 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AZD1222
Description: Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
Study NCT05144022 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Bungee jump
Description: Bungee jump from a cran
Study NCT05144022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bungee jump
Description: Bungee jump from a cran
Study NCT06394063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Telitacicept 160 mg SC every other week
Study NCT06394063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Telitacicept
Study NCT06513702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transesophageal lung ultrasound (TELUS) guided recruitment maneuver
Description: 1. Lung reinflation guided by transesophageal lung ultrasound (TELUS) after cardiopulmonary bypass weaning~2. TELUS guided recruitment maneuver with continuous positive pressure of 30cmh20 for 20 seconds and 40cmh20 for 20 seconds during sternal wiring
Study NCT06513702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual bag lung reinflation
Description: After weaning of CPB, Lung will be reinflated by 5 deep manual bag infaltion until full inflation observed by the anesthetist.~During sternal wiring, Lung ultrasound will be examine - LUNG ultrasound score will be taken- no recruitment maneuver will be done in this contro group (Basically this group of patient is a routine practice in cardiac surgery
Study NCT06449625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Pen Injector [Ozempic]
Description: Semaglutide active drug
Study NCT06449625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: semaglutide placebo
Study NCT04987203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Tivozanib will be administered orally.
Study NCT04987203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered via intravenous infusion.
Study NCT04652934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic
Description: The Upper Limb Neurodynamic Test (ULNT1) technique described by Butler will be performed on the affected limb. This technique consists of performing shoulder depression, 90º shoulder abduction, hand, wrist and forearm in a neutral position, external rotation of the shoulder and extension of the elbow. After positioning the limb in this position, wrist flexion-extension movements will be performed smoothly and rhythmically of 20 movements every minute, for 3 minutes, three times per session with 1 minute of rest between each series.
Study NCT04652934 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mimic group
Description: The protocol used by Beneciuk et al. Will be used. This intervention consists of imitating NM without stressing the nervous system. It will be carried out as follow: a neutral cervical position will be maintained (0º of cervical inclination), 45º of shoulder abduction without depression, 45º of external rotation of the shoulder combined with 45º of elbow flexion with the forearm in pronation. Afterwards, 10 wrist flexion-extension movements will be performed at a rate of 6 seconds per cycle (3 seconds of flexion and 3 seconds of extension). The resistance that you will feel will stabilize when you change motion. Once the 10 cycles of movements have been carried out, a wrist flexion will be maintained for 10 seconds.
Study NCT06411821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: 300 mg twice daily, for every 28-day cycle.
Study NCT05498272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg orally twice a day (D1-D30) for 6 Cycles (30 day Cycles)
Study NCT05498272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Description: Total duration of therapy will be for 180 days with use of agent as per institutional standards
Study NCT05815810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attuned: A mobile application
Description: Subjects will undergo voice and communication modification therapy via the Attuned application. This consists of an 11 week program consisting of different modules to learn how to modify voice (e.g., pitch, intonation, resonance). At the end of each module, participants will be given exercises to practice what they learned.
Study NCT05815810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Voice Modification Therapy
Description: Subjects will undergo standard of care in-person voice modification therapy at Ithaca College.
Study NCT02974582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to smoking advertising with coupon
Description: Direct mail marketing of smoking advertising with discount coupon
Study NCT02974582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to smoking advertising without coupons
Description: Direct mail marketing of smoking advertising without discount coupon
Study NCT02974582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to non health related images
Description: Control group
Study NCT06061471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK111
Description: AK111 regimen 1-subcutaneous injection,until week 24.
Study NCT06061471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK111
Description: AK111 regimen 2-subcutaneous injection,until week 24.